Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.

@article{Chun2006SynergisticEO,
  title={Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.},
  author={Patrick Y Chun and Felix Feng and Ashley M Scheurer and Mary Abby Davis and Theodore Steven Lawrence and Mukesh Kumar Nyati},
  journal={Cancer research},
  year={2006},
  volume={66 2},
  pages={
          981-8
        }
}
Although the combination of gemcitabine and radiation produces a high frequency of complete responses in the treatment of locally advanced head and neck cancer, substantial toxicity suggests that an improvement in the therapeutic index is required. The purpose of this study was to determine if gefitinib could improve the efficacy of gemcitabine and if drug schedule is important. We hypothesized that gemcitabine followed by gefitinib would be superior to the opposite order because of both cell… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma

  • Molecular and clinical oncology
  • 2013
VIEW 5 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2007
VIEW 9 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Radiosensitizing nucleosides.

  • Journal of the National Cancer Institute
  • 1996
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Cdc 25 A and ERK interaction : EGFRindependent ERK activation by a protein phosphatase Cdc 25 A inhibitor , compound 5

Z Wang, B Zhang, M Wang, BI Carr
  • J Cell Physiol
  • 2005

Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG

MJ Moore, D Goldstein, J Hamm
  • Gastrointestinal Cancers Symposium (Meeting Abstracts)
  • 2005
VIEW 1 EXCERPT

Epidermal growth factor receptor inhibitors in clinical development.

  • International journal of radiation oncology, biology, physics
  • 2004

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…